Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Radiant Innovation's Debt-to-EBITDA or its related term are showing as below:
ROCO:3373's Debt-to-EBITDA is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 1.6 * Ranked among companies with meaningful Debt-to-EBITDA only.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Radiant Innovation Debt-to-EBITDA Related Terms
Radiant Innovation Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Radiant Innovation's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:3373 vs ABT, SYK, MDT: Debt-to-EBITDA Comparison
For the Medical Devices subindustry, Radiant Innovation's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Radiant Innovation Debt-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Radiant Innovation's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Radiant Innovation's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Radiant Innovation (ROCO:3373) has a Debt-to-EBITDA of 0.00 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Radiant Innovation. According to the industry distribution chart, Radiant Innovation ranks #999999 out of 475 companies in the Medical Devices & Instruments industry.
Is Radiant Innovation's Debt-to-EBITDA too high?
Radiant Innovation's current Debt-to-EBITDA is 0.00. Based on the distribution chart, Radiant Innovation ranks #999999 out of 475 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Radiant Innovation has a GF Score™ of 65/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Radiant Innovation's Debt-to-EBITDA compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Radiant Innovation ranks #999999 out of 475 companies for Debt-to-EBITDA. This places Radiant Innovation in the lower half of its industry. The industry median Debt-to-EBITDA is 1.60. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Devices & Instruments company?
The median Debt-to-EBITDA among Medical Devices & Instruments companies is 1.60, based on 475 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Radiant Innovation. For the Medical Devices & Instruments industry, the median Debt-to-EBITDA is 1.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Radiant Innovation's current Debt-to-EBITDA is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Radiant Innovation stock overvalued right now?
Based on GuruFocus' analysis, Radiant Innovation (ROCO:3373) is currently considered Fairly Valued. The stock's GF Value™ is NT$17.05, compared to a current price of NT$16.75 — trading 1.8% below its estimated fair value. The current Debt-to-EBITDA is 0.00. Radiant Innovation's overall GF Score™ is 65/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Radiant Innovation (ROCO:3373), the current Debt-to-EBITDA is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Radiant Innovation (ROCO:3373) Overvalued in 2026?
Based on GuruFocus' analysis, Radiant Innovation stock appears to be undervalued.
The current stock price of NT$16.75 is trading 1.8% below its estimated GF Value™ of NT$17.05.
GuruFocus considers Radiant Innovation to be Fairly Valued.
Key valuation signals for ROCO:3373:
Debt-to-EBITDA: 0.00
GF Value™: NT$17.05 vs. price of NT$16.75 (1.8% below fair value)
No single metric tells the full story. See the ROCO:3373 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Radiant Innovation Inc is engaged in the manufacture and distribution of medical instruments in Taiwan. It provides infrared ear thermometers, multi-function thermometers, infrared forehead thermometers as well as carbon dioxide detectors.
65GF Score
Get the complete analysis for ROCO:3373
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:3373 has been successfully added to your 
